In the lysosomal storage disorders area, the NanoBriva™ platform allows for the design and production of novel recombinant therapeutic enzymes fused to innovative peptidic linkers engineered to confer both superior tissue penetration including in hard to target organs such as the brain, and slow-release pharmacokinetics.
Studies in rodents have shown the ability of recombinant lysosomal enzymes fused to these innovative peptides to cross the blood brain barrier while remaining active.
Samabriva is developing its own therapeutic products and is keen to establish partnerships to develop new first-in-class products in the Lysosomal Storage Disorder area as part of a collaboration.
If you are interested
CONTACT US
